Company intelligence / Profile preview

Inhibikase Therapeutics, Inc.

Atlanta, Georgia, United Statesinhibikase.com ↗

Ownership: Public · IKT
Development stage: Phase 2

Overview

Currently advancing IkT-001Pro into Phase 2b '702' trial for Pulmonary Arterial Hypertension (PAH). Previously discontinued risvodetinib (IkT-148009) for Parkinson's disease in January 2025 after Phase II trial showed safety but failed to demonstrate significant efficacy in primary endpoints.

Therapeutic areas: GastroenterologyCardiovascularNeurology
Modalities: Small moleculesProtein kinase inhibitorsAbelson Tyrosine Kinase inhibitors
Industry: Biotech

Drug pipeline

3 assets

IKT-001

2 more assets in the full pipeline.

Request access →

Financials

Market cap: $318.2M
Total revenue: $0
Enterprise value: $159.2M

Beyond the preview

Go deeper on Inhibikase Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inhibikase Therapeutics, Inc..

Explore the full profile